MDNews - Lower Hudson/Bronx

May 2017

Issue link: https://viewer.e-digitaledition.com/i/821079

Contents of this Issue

Navigation

Page 9 of 23

says. " Bot h of t hese moda lities a re revolut iona r y pa i n-rel iev- ing therapies." PUMPING SYMPTOMS AWAY Neuromodu lation by way of a n i n t r a t h e c a l p u m p i s a n o t h e r innovative treatment frequently employed by Dr. Snyder for pa in. An intratheca l pump consists of a catheter a nd a device that deliver liquid pa in medication into the a ffected a rea of the spine. " We i mpla nt a la rge nu mber of i nt r a t he c a l pu mp s , mo s t ly w ith baclofen, for patients who have mu ltiple sclerosis, spi na l cord injur y, cerebra l pa lsy a nd pa i n a s s o ci at e d w it h s t r oke ," D r. S n y d e r s a y s . " Fo r t h e s e patients, intratheca l pumps ca n be miraculous because the device a llows for continuous infusion of a low dose of baclofen — which ca n be titrated to exactly the right dose — to optimize a patient 's spasticit y." A s Dr. Snyder ex pla ins, patients w ith intractable pa in a re a lso potentia l ca ndidates for intratheca l pumps. They a re t y pica lly admitted to the hospita l for a shor t stay a nd administered a tempora r y tria l medication. Mimicking a perma nently placed pump, a catheter is placed to deliver medication direct ly to the ner ves in the spine, a nd if the patient shows improvement in his or her pain level, Dr. Snyder a nd his tea m consider perma nent impla ntation of the pump. " The prima r y adva ntages of the intratheca l pump a re the dose is lower tha n that of ora l meds a nd is delivered exactly where it 's needed, providing the patient with compa rable or superior results to ora l medications, in addition to a much sa fer side-ef fect prof i le," Dr. Snyder says. " Fur thermore, the pea ks a nd troughs that occur with ora l dosing lead to intolera nce a nd worsening pa in. Because the pump r uns continuously, these potentia l effects a re minimized." SEIZING CONTROL OF CONVULSIVE ATTACKS Dr. Snyder was the first neurosurgeon in Long Island to implant the revolutionary NeuroPace, a technology for seizure control in epileptic patients. Epilepsy a–ects an estimated 3 million Americans and 65 million people worldwide, according to Citizens United for Research in Epilepsy, and costs the U.S.¦roughly $15.5¦billion annually. "The NeuroPace device allows us to treat epilepsy in a safe titratable fashion by treating electrical disturbances in the brain with electricity," Dr. Snyder says. "The No. 1 advantage of this new device and therapy is it's a nondestructive procedure. We can operate on eloquent areas of the brain that have a specific function that we otherwise couldn't safely operate on. However, this procedure is a safe, reversible treatment that doesn't entail removing any brain tissue." Dr. Snyder and his team conduct diagnostic testing prior to the procedure to identify the precise location in the brain where seizures begin. During the procedure, leads are positioned at the seizure source and the neurostimulator is placed in the skull, hidden under the scalp. This revolutiona r y surgica l technolog y a nd technique, however, is only applicable to focal epilepsies. Epilepsies are defined as focal or general. General epilepsies begin synchronously throughout the brain, whereas foca l epilepsies start in a specific, identifiable place. "By placing the electrodes at the location where the seizures start, the implant is able to detect and stop a seizure before it even begins." Roughly one in three people with epilepsy do not benefit from medication management of seizures, making NeuroPace a source of newfound hope. LIFE-ENHANCING ALTERNATIVES Leading-edge neurosurgeries, such as DBS, NeuroPace and neuromodulation for pain, have provided patients su–ering from disabling e–ects of many neurological disorders with safe alternatives that address symptom relief. "Patients fare extraordinarily well with these therapies," Dr. Snyder says. "Many patients who haven't found relief from other medical therapies would significantly benefit from an evaluation and potentially treatment from these revolution- ary technologies." For more information about functional and restorative neurosurgical options available at Neurological Surgery, P.C., visit nspc.com. ■ Dr. Snyder reviews the location of implanted intracranial grids for long-term seizure monitoring. 1 0 C O V E R F E A T U R E

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - May 2017